| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Tobey Sommer maintains Insperity (NYSE:NSP) with a Hold and lowers the price target from $50 to $35.
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patie...
On November 3, 2025, a subsidiary of Insperity, Inc. (the "Company") entered into an amendment to its arrangement with ...
Insperity (NYSE:NSP) is looking for Q4 GAAP EPS of $(1.07)-$(0.44) vs $(0.18) analyst estimate..
Insperity (NYSE:NSP) lowers FY2025 GAAP EPS guidance from $0.59-$1.29 to $(0.38)-$0.25 vs $1.01 analyst estimate..
Insperity (NYSE:NSP) lowers FY2025 Adj EPS guidance from $1.81-$2.51 to $0.84-$1.47 vs $2.11 analyst estimate..